Lytix's partner Verrica fully recruited its phase II study in basal cell carcinoma in January, with a topline readout expect in H1 2024. This will be a major catalyst that can change the investment case. Lytix will focus the future development of LTX-315 on the neoadjuvant instead of refractory setting, which increases its sales potential, but will also mean a longer time to the market.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/